Ligence, a Vilnius-based startup focused on cardiac diagnostics, has secured €3 million in seed funding, with Simpact Ventures leading the investment. Other contributors include Coinvest Capital, the European Innovation Council (EIC) Fund, Lemonade Stand, and angel syndicate NGL. The company has developed AI-powered software that automates the analysis of cardiac ultrasound images, aiming to support cardiologists in making more accurate and timely diagnoses. The funding will help Ligence expand its reach and further its mission to improve diagnostic processes, reduce the workload on healthcare professionals, and enhance patient care.
Ligence is a health technology company focused on improving cardiac diagnostics through the use of artificial intelligence. The company has developed software that automates the analysis of cardiac ultrasound images, helping cardiologists make more accurate and efficient diagnoses. By reducing the time spent on manual image review, Ligence’s technology allows healthcare providers to focus more on patient care. The software integrates with existing hospital systems, following established clinical guidelines to ensure consistent and reliable results. Ligence’s goal is to enhance the diagnostic process, making heart disease detection faster and more accessible while supporting the broader healthcare system.
“The investors’ confidence once again shows that the company’s strategic direction is the right one: the world’s biggest killer – cardiovascular disease – and one of the key tests to diagnose it, cardiac ultrasound, deserve more attention,” says Ligence CEO Arnas Karužas. “With an aging population, a growing number of comorbidities, and a number of risk factors that we are still fighting, accurate and rapid diagnosis of heart disease is more important than ever.”
“Impact investing is an investment strategy that seeks to generate not only a financial return but also a measurable benefit for society or the environment,” explains Wojciech Majewski, a partner at Simpact Ventures. “Ligence aims to improve the availability and accuracy of heart disease diagnostics, reducing clinical workload and allowing doctors to spend more time with patients.”
“For us, one of the most exciting aspects of investing is supporting not only the business potential but also the purpose and mission of the team. Ligence has already won the ‘Startup Fair. Pulse 2024’ award at the largest startup event in the Baltics, demonstrating that the investment community recognizes both the team’s potential and the positive impact of their product on society,” says Viktorija Trimbel, Director of Coinvest Capital.
Justinas Pašys, Founder and CEO at NGL, says: “Our syndicate of 53 angels has decided to back Ligence after engaging with the team since 2020 and witnessing their ability to develop a world-class product. With strong traction, strategic partnerships, and ongoing clinical trials at top US hospitals, Ligence is well-positioned for significant growth. We believe the startup’s solution will enable faster and more accurate heart disease diagnoses, improving patient outcomes and increasing the efficiency of healthcare systems.”
Ligence’s social mission is to increase the availability and accuracy of cardiac ultrasound for patients to enable earlier diagnosis, better risk assessment and patient screening. For doctors, this helps to reduce manual workload, and leave more time to interact with patients. The company puts its resources first in this social mission.
Ligence software is already in use by customers in Lithuania and across other European countries, including Poland, Switzerland, Germany, France, Spain, Portugal, and the United Kingdom, and is currently being tested in Morocco. Clinical trials are underway in the United States, Germany, the Netherlands, Poland, and Lithuania.
Click to read more funding news.
Read the orginal article: https://arcticstartup.com/ligence-raises-e3-million/
